Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_assertion type Assertion NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_head.
- NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_assertion description "[It is also possible that therapies employing dopamine D1/D2 receptor agonists or COMT inhibitors will be beneficial for patients with negative symptoms in schizophrenia and bipolar disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_provenance.
- NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_assertion evidence source_evidence_literature NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_provenance.
- NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_assertion SIO_000772 15952869 NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_provenance.
- NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_assertion wasDerivedFrom befree-2016 NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_provenance.
- NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_assertion wasGeneratedBy ECO_0000203 NP499199.RAozK17m7Cyjh_F4hnjBb06MWHa2LKgFDzSlvcY9laDiM130_provenance.